Literature DB >> 12913834

Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety.

David W Scheifele1, Scott A Halperin.   

Abstract

In Canada since 1993 the nation's passive system for reporting postimmunization adverse events has been supplemented by the active surveillance of inpatients at 10 to 12 pediatric referral centers, a system referred to as the Immunization Monitoring Program, Active. Participating centers are located from coast-to-coast and receive referrals from every province and territory. Approximately 20 percent of the population aged 0 to 12 years lives in the immediate vicinity of these centers. Nurse monitors at each center search for numerous target conditions, including postimmunization adverse events and vaccine-preventable infections. Vaccine safety observations have included (1) a substantial decrease in the risk of the development of febrile seizures and hypotonic-hyporesponsive episodes since the country switched from whole-cell to acellular pertussis-containing vaccines, (2) no evidence for encephalopathy resulting from the latter vaccines, (3) a generally benign outcome with postimmunization thrombocytopenia cases, and (4) an unexpectedly high rate of disseminated bacille Calmette-Guérin infections among aboriginal infants. Concomitant disease surveillance has been important for sustaining the surveillance system because few postimmunization adverse events require hospital admission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913834     DOI: 10.1016/s1045-1870(03)00036-0

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  18 in total

Review 1.  When should vaccination be contraindicated in children?

Authors:  Laura Lane; Arlene Reynolds; Mary Ramsay
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Has the change to acellular pertussis vaccine improved or worsened pertussis control?

Authors:  Scott A Halperin; Gaston De Serres
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

3.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

4.  An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.

Authors:  Kumanan Wilson; Katherine M Atkinson; Jacqueline Westeinde; Cameron Bell; Kim Marty; Dean Fergusson; Shelley L Deeks; Natasha Crowcroft; Julie A Bettinger
Journal:  Hum Vaccin Immunother       Date:  2016-02-23       Impact factor: 3.452

5.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

6.  An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada.

Authors:  Ana Komparic; Maxwell J Smith; Alison Thompson
Journal:  Public Health Ethics       Date:  2015-01-29       Impact factor: 1.940

7.  The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases.

Authors:  J A Bettinger; S A Halperin; W Vaudry; B J Law; D W Scheifele
Journal:  Can Commun Dis Rep       Date:  2014-12-04

8.  Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003.

Authors:  David Scheifele; Scott Halperin; Barbara Law; Arlene King; Scott Halperin; Robert Morris; Charles A Janeway; Pierre Déry; Marc Lebel; Dorothy Moore; Nicole Le Saux; Elizabeth Ford-Jones; Ben Tan; Taj Jadavji; Wendy Vaudry; Wikke Walop; Joanne Embree; John Waters
Journal:  CMAJ       Date:  2005-01-04       Impact factor: 8.262

9.  Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.

Authors:  A D Cox; L Barreto; M Ulanova; M G Bruce; Rsw Tsang
Journal:  Can Commun Dis Rep       Date:  2017-05-04

10.  Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013-2016.

Authors:  N Ahmadipour; K Watkins; M Fréchette; C Coulby; H Anyoti; K Johnson
Journal:  Can Commun Dis Rep       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.